Jim Simons T Scan Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 169,706 shares of TCRX stock, worth $210,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares

169,706

Previous 10,600 1501.0%

Holding current value

$210,435

Previous $32,000 631.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 14, 2025	BUY	$1.35 - $3.12 $214,793 - $496,410	159,106 Added 1501.0%	169,706 $234,000
Q4 2024 Feb 13, 2025	SELL	$2.93 - $5.94 $185,762 - $376,596	-63,400 Reduced 85.68%	10,600 $32,000
Q3 2024 Nov 13, 2024	SELL	$4.97 - $7.49 $29,820 - $44,940	-6,000 Reduced 7.5%	74,000 $368,000
Q2 2024 Aug 09, 2024	BUY	$5.85 - $9.51 $193,050 - $313,830	33,000 Added 70.21%	80,000 $468,000
Q1 2024 May 13, 2024	BUY	$4.89 - $8.3 $123,716 - $209,990	25,300 Added 116.59%	47,000 $373,000
Q4 2023 Feb 13, 2024	BUY	$2.66 - $6.76 $10,640 - $27,040	4,000 Added 22.6%	21,700 $127,000
Q3 2023 Nov 14, 2023	SELL	$2.04 - $2.94 $264,714 - $381,500	-129,762 Reduced 88.0%	17,700 $45,000
Q2 2023 Aug 11, 2023	BUY	$1.64 - $4.85 $222,813 - $658,930	135,862 Added 1171.22%	147,462 $369,000
Q1 2023 May 12, 2023	BUY	$1.66 - $3.32 $2,656 - $5,312	1,600 Added 16.0%	11,600 $24,000
Q4 2022 Feb 13, 2023	BUY	$1.49 - $3.33 $14,900 - $33,300	10,000 New	10,000 $16,000
Q2 2022 Aug 12, 2022	SELL	$1.65 - $3.58 $21,945 - $47,614	-13,300 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.8 - $5.4 $37,240 - $71,820	13,300 New	13,300 $37,000

Others Institutions Holding TCRX

# of Institutions

Shares Held

39.8M

Call Options Held

Put Options Held

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $23.5M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account